# ANTICANCER AGENT HALAVEN® APPROVED IN THE PHILIPPINES FOR NEW INDICATION FOR TREATMENT OF SOFT TISSUE SARCOMA

*SECOND COUNTRY IN ASIA AFTER JAPAN TO APPROVE HALAVEN FOR SOFT TISSUE SARCOMA*

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ñEisaiò) announced today that its subsidiary in the Philippines HI-Eisai Pharmaceutical Inc., has received approval for a new indication for its in-house discovered anticancer agent Halaven® (eribulin mesylate) for the treatment of soft tissue sarcoma. Halaven is the first and only single agent to demonstrate a statistically significant overall survival (OS) benefit in a Phase III trial in patients with advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma). The Philippines is the second country in Asia in which Halaven has been approved for the soft tissue sarcoma indication following approval in Japan, the United States and Europe.

In a Phase III study (Study 309)[1]

Together with providing Halaven for patients with soft tissue sarcoma in the Philippines, Eisai is working to submit applications seeking approval for an indication covering soft tissue sarcoma throughout Asia. Furthermore, Eisai remains committed to maximizing the clinical value as well as exploring the potential clinical benefits of Halaven as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

**[Notes to editors]**

**1. About Halaven**

Halaven is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action.

### 3. About Study 309[1]

Conducted primarily in Europe and the United States, Study 309 was a multicenter, open-label, randomized Phase III study comparing the efficacy and safety of Halaven versus dacarbazine in 452 patients (aged 18 or over) with locally advanced, recurrent or